Detailed Information

Cited 7 time in webofscience Cited 2 time in scopus
Metadata Downloads

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

Authors
Shin, Seung YongPark, Soo JungKim, YoungIm, Jong PilKim, Hyo JongLee, Kang-MoonKim, Ji WonJung, Sung-AeLee, JunKang, Sang-BumShin, Sung JaeKim, Eun SunKim, You SunKim, Tae OhKim, Hyun-SooPark, Doing IlKim, Hyung KilKim, Eun SooKim, Young-HoKim, Do HyunTeng, DennisKim, Jong-HwaKim, WonyongChoi, Chang HwanIBD Research Group of the Korean Association for the Study of Intestinal Diseases
Issue Date
Jul-2022
Publisher
대한장연구학회
Keywords
Inflammatory bowel disease; Tumor necrosis factor inhibitors; Treatment outcome
Citation
Intestinal research, v.20, no.3, pp.350 - 360
Indexed
SCOPUS
KCI
Journal Title
Intestinal research
Volume
20
Number
3
Start Page
350
End Page
360
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/54576
DOI
10.5217/ir.2021.00049
ISSN
1598-9100
Abstract
Background/Aims This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). Methods A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score. Results A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients. Conclusions ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Eun Sun photo

Kim, Eun Sun
Anam Hospital (Department of Gastroenterology and Hepatology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE